Qiagen (NYSE:QGEN) Upgraded at Hsbc Global Res

Hsbc Global Res upgraded shares of Qiagen (NYSE:QGEN) to a hold rating in a report issued on Thursday morning, Zacks.com reports.

A number of other brokerages have also issued reports on QGEN. Robert W. Baird raised their target price on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Wolfe Research upgraded Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a report on Thursday, June 27th. Finally, HSBC lowered Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Qiagen currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.12.

Qiagen Stock Performance

NYSE:QGEN opened at $43.00 on Thursday. The company has a current ratio of 1.77, a quick ratio of 1.46 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $9.81 billion, a P/E ratio of 143.09, a price-to-earnings-growth ratio of 3.36 and a beta of 0.39. The firm has a 50-day moving average price of $45.10 and a two-hundred day moving average price of $43.54. Qiagen has a twelve month low of $34.74 and a twelve month high of $47.44.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.52 by $0.03. The business had revenue of $496.00 million during the quarter, compared to analysts’ expectations of $495.45 million. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The company’s revenue was down .2% on a year-over-year basis. During the same period last year, the company posted $0.53 EPS. As a group, research analysts expect that Qiagen will post 2.15 earnings per share for the current fiscal year.

Institutional Trading of Qiagen

A number of institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC grew its stake in Qiagen by 806.5% during the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after buying an additional 500 shares during the period. Toronto Dominion Bank purchased a new stake in Qiagen during the 2nd quarter worth $27,000. Riverview Trust Co purchased a new stake in Qiagen during the 1st quarter worth $28,000. Park Place Capital Corp acquired a new stake in Qiagen in the 1st quarter valued at $36,000. Finally, Massmutual Trust Co. FSB ADV raised its position in Qiagen by 39.8% in the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after purchasing an additional 243 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.